Silence Therapeutics Q1 net loss widens to $28.5M; cash runway extended into 2028

Silence Therapeutics plc

2025-Q1 EPS reported -$0.20 revenue$142,000

Cash and short-term investments $136.5M at Mar 31, 2025, down from $147.3M at Dec 31, 2024.
Net loss $28.5M ($0.20/ADS) vs $2.3M ($0.02) in Q1 2024; R&D up $9.0M to $20.8M.
Divesiran Phase 2 SANRECO enrollment on track to complete by year-end 2025; EHA presentation June 12-15.
Cost savings initiatives implemented to extend cash guidance into 2028; Phase 3 readiness for zerlasiran ongoing.
Appointed Tim McInerney to Board of Directors effective May 5, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.